<DOC>
	<DOCNO>NCT02834988</DOCNO>
	<brief_summary>The investigator hypothesize perform SLND ( instead complete lymphadenectomy ) decrease complication hemorrhage , low extremity lymphedema lymphocyst formation enhance quality life EC patient low risk nodal involvement . The investigator also hypothesize SLND effective method stag patient . Studies show SLN map identifies positive lymph node woman newly diagnose EC prognostic information obtain SLND could guide selection adjuvant treatment improve overall survival . Using SLND alternative may also additional medical economic impact . Prolonged hospitalization associate cost avoid shorten overall surgery duration .</brief_summary>
	<brief_title>Sentinel Lymph Node Dissection ( SLND ) Patients With Apparent Early Stage Endometrial Cancer</brief_title>
	<detailed_description>This interventional , prospective , non-therapeutic study evaluate clinical utility SLND detect nodal metastasis early stage endometrial cancer . Patients undergo surgical staging EC ( sentinel lymph node dissection ( SLND ) via laparotomy , laparoscopy robotic surgery , ±hysterectomy , ±bilateral salpingo-oophorectomy ( BSO ) ) . Pelvic paraaortic lymphadenectomy may ( may ) also perform addition SLND , discretion Surgeon . Sentinel lymph node ( SLN ) remove ; , patient SLND . Pelvic washing may also obtain . Pathology assessment nodal metastasis perform node remove ( SLN enlarge remove lymph node ) . Patients stag use International Federation Gynecology Obstetrics ( FIGO ) criterion classify risk stratum ( either low high risk EC ) per Modified Mayo Criteria . Based pathologic risk assessment FIGO stage , patient may assign receive adjuvant treatment discretion treat Investigator per institutional guideline ; per-protocol treatment plan .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Fluorophosphate</mesh_term>
	<criteria>1 . Patients must histologically and/or cytologically confirm endometrial cancer . 2 . Clinically apparent early stage endometrial cancer ( i.e . disease confine uterus preoperative work ) . 3 . Surgical candidate operable tumor ( patient eligible willing undergo surgery management endometrial cancer ) deem institutional surgeon . 4 . Females age 18 year old . 5 . Eastern Cooperative Oncology Group ( ECOG ) /Gynecologic Oncology Group ( GOG ) performance status ≤ 2 . 6 . Patients must normal organ marrow function define : White blood cell ( WBC ) ≥3,000/ul Platelets ( PLT ) ≥100,000/ul Total bilirubin &gt; 2.0 x upper limit institutional normal ( ULN ) Creatinine ≤ 1.5 x ULN ( upper limit institutional normal ) 7 . Ability understand willingness sign write informed consent document . 1 . Patients lymphadenopathy and/or evidence metastasis , either clinically palpable and/or preoperative radiological imaging . 2 . Any preoperative adjuvant therapy endometrial cancer ( e.g . prior pelvic/abdominal radiotherapy ( RT ) , chemotherapy , retroperitoneal surgery ) . 3 . Patients may receive investigational agent . 4 . Pregnant breastfeeding patient . A pregnancy test require Screening perimenopausal patient hysterectomy . 5 . Central Nervous System ( CNS ) restriction ( i.e . brain metastasis ) . 6 . History allergic reaction hypersensitivity attribute compound similar chemical biologic composition phenylmethane , iodine , isosulfan blue , indigocyanine green ( ICG ) agent ( ) use study . If allergy one possible compound , patient enrol treat Investigator take document precaution ensure agent patient allergic use . 7 . Any uncontrolled , intercurrent illness include limited concomitant cancer , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . 8 . Any serious medical psychiatric illness/condition likely judgment Investigator ( ) interfere limit compliance study requirements/treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Endometrial Cancer</keyword>
	<keyword>Sentinel Lymph Node Dissection</keyword>
	<keyword>SLND</keyword>
</DOC>